Novavax Announces Release Date of First Quarter 2006 Financial Results and Investor Conference Call
May 05 2006 - 2:46PM
PR Newswire (US)
MALVERN, Pa., May 5 /PRNewswire-FirstCall/ -- Novavax, Inc.
(NASDAQ:NVAX) today announced that it will report its first quarter
financial results in a Press Release to be issued after 7:00 a.m.
EDT on May 15, 2006. The Company will subsequently hold an investor
conference call to discuss its financial results at 10:00 a.m. EDT
on May 15, 2006. The call will be hosted by Mr. Gary C. Evans,
Chairman of the Board and Dr. Rahul Singhvi, President and CEO of
Novavax. Other participants on the call will include senior
management of Novavax. A question and answer session will follow
the financial results overview. The dial-in number for the
conference call is 1-800-599-9795 (International 1-617-786-2905),
pass code 23869726. A live audio webcast of the conference call
will be available through http://www.novavax.com/. Please connect
to this website at least 15 minutes prior to the conference call to
ensure adequate time for any software download that may be needed
to hear the webcast. A replay of the webcast will be available for
90 days starting on May 15, 2006 at http://www.novavax.com/. A
replay of the conference call will also be available by telephone
starting on May 15, 2006 at 12:00 noon through May 22, 2006. To
access the replay, dial (888) 286-8010 and enter pass code 18031915
followed by the number sign. About Novavax, Inc. Novavax is focused
on creating differentiated, value-added pharmaceutical and vaccine
products and technologies. The company's technology platforms
include the virus-like particle (VLP) manufacturing technology
utilizing the baculovirus expression system in insect cells, as
well as novel vaccine adjuvants based on Novasomes(R),
non-phospholipid vesicles and dendrimer technologies. The company
is developing a pandemic flu vaccine against H5N1, H9N2 and other
avian influenza viruses and a seasonal flu vaccine against human
influenza strains using its VLP and Novasome adjuvant technologies.
Novavax's drug delivery technologies include the micellar
nanoparticle (MNP) technology which is the basis for the
development of its first FDA-approved product, ESTRASORB(R). In
addition to MNP, Novavax drug delivery technologies include
Novasomes(R) and Sterisomes(R), solvent and oil free emulsions for
subcutaneous depot injection. The company has several products
utilizing the MNP technology in various stages of development.
Forward-Looking Statements Statements made in this press release
that state Novavax's or management's intentions, hopes, beliefs,
expectations, or predictions of the future are forward-looking
statements. Forward-looking statements include but are not limited
to statements regarding usage of cash, product sales, future
product development and related clinical trials and future research
and development, including FDA approval. Novavax's actual results
could differ materially from those expressed in such
forward-looking statements. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the
Company, or industry results, to be materially different from those
expressed or implied by such forward-looking statements. Such
factors include, among other things, the following: general
economic and business conditions; ability to enter into future
collaborations with industry partners, competition; unexpected
changes in technologies and technological advances; ability to
obtain rights to technology; ability to obtain and enforce patents;
ability to commercialize and manufacture products; ability to
establish and maintain commercial-scale manufacturing capabilities;
results of clinical studies; progress of research and development
activities; business abilities and judgment of personnel;
availability of qualified personnel; changes in, or failure to
comply with, governmental regulations; the ability to obtain
adequate financing in the future through product licensing,
co-promotional arrangements, public or private equity financing or
otherwise; and other factors referenced herein. Additional
information is contained in Novavax's annual report on Form 10K for
the year ended December 31, 2005 incorporated herein by reference.
Statements made herein should be read in conjunction with Novavax's
annual and quarterly reports filed with the SEC. Copies of these
filings may be obtained by contacting Novavax at 508 Lapp Road,
Malvern, PA 19355 Tel 484-913-1200 or the SEC at
http://www.sec.gov/. DATASOURCE: Novavax, Inc. CONTACT: Cheryl
Marley, Novavax, Inc., +1-484-913-1202, Web site:
http://www.novavax.com/
Copyright
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From May 2024 to Jun 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Jun 2023 to Jun 2024